Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have received an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $68.6667.

A number of equities research analysts have recently weighed in on GPCR shares. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Monday, November 24th. Lifesci Capital upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research report on Monday, September 8th. JMP Securities lowered their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Zacks Research lowered shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Structure Therapeutics in a research note on Friday.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently bought and sold shares of GPCR. State of Wyoming purchased a new stake in Structure Therapeutics in the second quarter worth $28,000. EverSource Wealth Advisors LLC lifted its position in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the period. National Bank of Canada FI lifted its position in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock worth $51,000 after purchasing an additional 2,766 shares during the period. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after purchasing an additional 820 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Structure Therapeutics by 29.1% during the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Trading Up 4.6%

Shares of Structure Therapeutics stock opened at $35.81 on Friday. The firm has a market capitalization of $2.07 billion, a PE ratio of -29.35 and a beta of -1.63. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $40.29. The business’s 50-day moving average price is $30.55 and its 200-day moving average price is $23.98.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). As a group, analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.